Ladenburg initiated coverage of Ceribell (CBLL) with a Buy rating and $32 price target The company has a first-mover advantage in scaling rapid electroencephalography technology for acute neurological care, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CBLL:
- Ceribell, Inc. Announces Executive Compensation Adjustments
- CeriBell’s Earnings Call: Strong Growth Amid Challenges
- Six new option listings and one option delisting on February 26th
- Strong Financial Performance and Strategic Growth Initiatives Drive Buy Rating for Ceribell, Inc.
- Ceribell, Inc.: Strong Financial Performance and Strategic Investments Justify Buy Rating